Technical and Clinical Aspects of Cascade Filtration Plasma Exchange (CFPE)
| العنوان: | Technical and Clinical Aspects of Cascade Filtration Plasma Exchange (CFPE) |
|---|---|
| المؤلفون: | J. F. Quaranta, Sanderson F, Maiolini R, E. Cassuto-Viguier, H. Duplay |
| المصدر: | The International Journal of Artificial Organs. 6:309-314 |
| بيانات النشر: | SAGE Publications, 1983. |
| سنة النشر: | 1983 |
| مصطلحات موضوعية: | Chromatography, Venous pressure, Chemistry, medicine.medical_treatment, Biomedical Engineering, Albumin, Medicine (miscellaneous), Bioengineering, General Medicine, Plasma, Plasma Substitutes, law.invention, Biomaterials, Cascade, law, Hemofiltration, medicine, Filtration, Whole blood |
| الوصف: | Cascade filtration plasma exchanges (CFPE) were realized using an hemofiltration system (HFS) coupled to 2 filters with different pore sizes. The first one (F1 = plasma-separator; Asahi plasmaflo HI-05) separates plasma from whole blood, the second one (F2 = plasma filter; Asahi XK-60, Kuraray EVAL 2A or 4A) filtrates high molecular weight (MW) components from the separated plasma. F2 filtrate returns to patient mixed with blood cells and 4% Albumin solution or Plasmion R* replacing plasma discarded (about 0.5-0.8 I for 1-1.5 plasma mass (PM) treated). The HFS is able i) to modulate the different pressures (veinous pressure, F1 and F2 transmembrane pressures (TMp)) using pumps speed variators, ii) to recirculate and concentrate extracted plasma and iii) to know F2 treated PM. Blood pressure, pulse rate and electrocardiogram were monitored during each CFPE session. Nineteen CFPE were performed for 8 patients selected among our PE indications, this selection taking into account presence or not of risk factors linked to disease e and/or to patient. Anti-histamine drugs were always infused before CFPE session. On a biological point of view, the problem lies into F2 selectivity which is relatively good for low (as Albumin) and high (as IgM) MW molecules which are returned to patient or discarded, but should be improved for the intermediate ones (as IgG). On a technical point of view, the plasma substitute quantity is reduced about six times. But the control of F2 TMp is not perfectly and the PM to be treated has to be investigated. On a clinical point of view and through biological results, diseases with high MW mediators may benefit of CFPE. Anyway, CFPE should be improved for IgG mediated diseases. |
| تدمد: | 1724-6040 0391-3988 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::c6e00548ad1a502939e21fa490f4ae21 https://doi.org/10.1177/039139888300600607 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi...........c6e00548ad1a502939e21fa490f4ae21 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17246040 03913988 |
|---|